Growing Bigger, Getting Cleaner

Novo Nordisk is pursuing net zero while growing faster than almost any pharmaceutical peer, reaching 45.2 million patients in 2024. That growth pushed Scope 1 and 2 emissions up 9% and Scope 3 up 24% in a single year.

Circular for Zero, formalised under Novo Nordisk's first CSRD-compliant Sustainability Statement in 2024, targets zero Scope 1 and 2 emissions by 2030 and a 33% Scope 3 cut by 2033 through supplier contracts, materials innovation, circular product design, and freight decarbonisation.

By 2024, 100% of production-site electricity came from renewables, over 1,800 suppliers had committed to renewable transitions, and the ReMed device take-back scheme lifted its recycling rate from 50% to 70% within a year.